Issue navigation
Volume 26, Issue Supplement_7, October 2024
Abstracts from the BNOS Cambridge 2024 Conference
BNOS 2024 ABSTRACTS: ORAL PRESENTATIONS
RECAPITULATING THE POST-SURGICAL BRAIN MICROENVIRONMENT OF ATYPICAL TERATOID RHABDOID TUMOURS TO IDENTIFY MEMBRANE PROTEINS FOR TARGETED THERAPY
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii1, https://doi.org/10.1093/neuonc/noae158.001
MULTIMODAL (5-ALA, TRACTOGRAPHY AND ULTRASOUND GUIDED) AWAKE CRANIOTOMY FOR GLIOBLASTOMA: MAXIMISING SAFE SURGICAL RESECTION
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii1, https://doi.org/10.1093/neuonc/noae158.002
THE MOLECULAR HISTORY OF IDH-MUTANT ASTROCYTOMAS WITHOUT ADJUVANT TREATMENT
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii1, https://doi.org/10.1093/neuonc/noae158.003
MAPPING GLIOMAS: A RADIOGRAPHIC AND SPATIAL ANALYSIS ACCORDING TO THE 2021 WHO CLASSIfiCATION
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii1–vii2, https://doi.org/10.1093/neuonc/noae158.004
DEVELOPING CEREBROSPINAL flUID METABOLOMIC BIOMARKERS FOR MINIMAL RESIDUAL DISEASE AND RELAPSE IN EPENDYMOMA AND MEDULLOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii2, https://doi.org/10.1093/neuonc/noae158.005
GLIOMA MONITORING VIA LONGITUDINAL INTRACRANIAL CSF CELL-FREE DNA: ONE PATIENT AT A TIME
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii2, https://doi.org/10.1093/neuonc/noae158.006
GLIOBLASTOMA IN THE UK POST WHO CNS 5: INITIAL fiNDINGS FROM THE HISTO-MOL GBM COLLABORATIVE
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii2–vii3, https://doi.org/10.1093/neuonc/noae158.007
LOCATE-SM PROTOCOL: LOCATION ORIENTED CORTICAL AND SUB-CORTICAL ASSESSMENT FOR THERAPEUTIC EVALUATION- SENSORY-MOTOR TESTING IN AWAKE CRANIOTOMY
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii3, https://doi.org/10.1093/neuonc/noae158.008
PRECISE-GBM: A RADIOGENOMIC MACHINE LEARNING BASED STUDY TO IDENTIFY PREDICTIVE RADIOMICS FOR EVALUATION OF CANCER IMMUNE SIGNATURE IN IDHW GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii3, https://doi.org/10.1093/neuonc/noae158.009
CELL-INTRINSIC METABOLIC PHENOTYPES IDENTIfiED IN GLIOBLASTOMA PATIENTS USING MASS SPECTROMETRY IMAGING OF 13C-LABELED GLUCOSE METABOLISM
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii3, https://doi.org/10.1093/neuonc/noae158.010
IN VIVO APPLICATION OF LOCAL DRUG DELIVERY SYSTEMS AGAINST MEDULLOBLASTOMA GROUP 3 AND ATYPICAL/TERATOID/RHABOID TUMOURS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii3–vii4, https://doi.org/10.1093/neuonc/noae158.011
EVALUATION OF AN ALLIED HEALTH PROFESSIONAL PREHABILITATION SERVICE IN NEURO-ONCOLOGY
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii4, https://doi.org/10.1093/neuonc/noae158.012
INVESTIGATING GLIOBLASTOMA STEM CELL DIFFERENTIATION IN HUMAN BRAIN 3D ORGANOID CO-CULTURES
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii4, https://doi.org/10.1093/neuonc/noae158.013
INTEGRATING ALLIED HEALTH PROFESSIONALS DURING THE ONCOLOGICAL TREATMENT PHASE FOR GLIOBLASTOMA PATIENTS: A CASE STUDY AT A UK CANCER CENTRE
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii4, https://doi.org/10.1093/neuonc/noae158.014
MODELLING GBM RECURRENCE: THE INflUENCE OF PERI-LESIONAL OEDEMA AND THE DISCONNECTOME
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii4, https://doi.org/10.1093/neuonc/noae158.015
ROR1 MRNA EXPRESSION IN GLIOMA - A NOVEL PROGNOSTIC BIOMARKER
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii4–vii5, https://doi.org/10.1093/neuonc/noae158.016
KINOME-WIDE SYNTHETIC LETHAL SCREEN IDENTIfiES PANK4 AS A MODULATOR OF TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii5, https://doi.org/10.1093/neuonc/noae158.017
OPTIC PATHWAY GLIOMAS AFTER TRANSITIONING INTO ADULTHOOD – AN INSTITUTIONAL EXPERIENCE
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii5, https://doi.org/10.1093/neuonc/noae158.018
MANAGEMENT OF THE OLDER PATIENT WITH GLIOBLASTOMA IN THE UK: AN INITIAL REPORT FROM THE HISTO-MOL GBM COLLABORATIVE
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii5–vii6, https://doi.org/10.1093/neuonc/noae158.019
FROM VEIN TO BRAIN: ENHANCING TRAffiCKING OF CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii6, https://doi.org/10.1093/neuonc/noae158.020
NOVEL HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS WITH ANTICANCER ACTIVITY IN MEDULLOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii6, https://doi.org/10.1093/neuonc/noae158.021
POSTOPERATIVE VISUAL fiELD DEfiCITS ARE NOT ASSOCIATED WITH REDUCTION IN QUALITY OF LIFE IN GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii6, https://doi.org/10.1093/neuonc/noae158.022
CHARACTERISATION OF THE RESPONSE OF PRE-CLINICAL MODELS OF GLIOMA TO METABOLIC THERAPIES USING IN VIVO MAGNETIC RESONANCE SPECTROSCOPY
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii6, https://doi.org/10.1093/neuonc/noae158.023
BNOS 2024 ABSTRACTS: POSTER PRESENTATIONS
EXPLORING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR) FAMILY IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii7, https://doi.org/10.1093/neuonc/noae158.024
APPLICATION OF IN VITRO MODELS: INCORPORATING BLOOD BRAIN BARRIER MODELS WITH GLIOMA, AND THE USE OF MICROflUIDICS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii7, https://doi.org/10.1093/neuonc/noae158.025
UNVEILING THE MECHANISTIC INSIGHTS OF ARGININE DEPRIVATION COMBINED WITH RADIOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii7, https://doi.org/10.1093/neuonc/noae158.026
TARGETING RESIDUAL CANCER FROM THE INVASIVE MARGIN OF GLIOBLASTOMA USING COMPUTATIONAL TOOLKITS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii7, https://doi.org/10.1093/neuonc/noae158.027
DIFFERENTIAL CELL SURFACE PROTEOMICS OF FLOTILLIN-1, HMGB1 AND AMINOPEPTIDASE N IN H3 MUTATED PAEDIATRIC HIGH-GRADE GLIOMAS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii7–vii8, https://doi.org/10.1093/neuonc/noae158.028
MITOCHONDRIAL MEMBRANE POTENTIAL IS A FUNCTIONALLY RELEVANT AXIS OF NON-GENETIC CELLULAR HETEROGENEITY IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii8, https://doi.org/10.1093/neuonc/noae158.029
THE EPIGENETIC REGULATORY PROTEIN CBX2 AS A NOVEL THERAPEUTIC TARGET FOR GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii8, https://doi.org/10.1093/neuonc/noae158.030
EVALUATING THE RELATIONSHIP BETWEEN RADIOTHERAPY CLINICAL TARGET VOLUME AND GAIT ACTIVITY IN HIGH GRADE GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii8, https://doi.org/10.1093/neuonc/noae158.031
AN EX-VIVO SPECTRAL AND LIFETIME-DECAY ANALYSIS OF 5-ALA DERIVED PPIX flUORESCENCE: OBJECTIVE flUORESCENCE MAPPING IN GLIOMA SURGERY
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii8–vii9, https://doi.org/10.1093/neuonc/noae158.032
PATTERNS OF RADIOTHERAPY PRACTICE FOR FUNCTIONING PITUITARY TUMOURS - A SURVEY OF UK CENTRES
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii9, https://doi.org/10.1093/neuonc/noae158.033
QUALITY OF LIFE IN PATIENTS WITH SKULL BASE CHORDOMA AND CHONDROSARCOMA TREATED WITH PENCIL BEAM SCANNING PROTON THERAPY
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii9, https://doi.org/10.1093/neuonc/noae158.034
NEURONAL INJURY DRIVES GLIOBLASTOMA INITIATION
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii9, https://doi.org/10.1093/neuonc/noae158.035
TARGETED THERAPY IN DIFFUSE INTRINSIC PONTINE GLIOMA: A COMPREHENSIVE REVIEW OF MONOCLONAL ANTIBODIES
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii9–vii10, https://doi.org/10.1093/neuonc/noae158.036
MULTI-OMIC INTEGRATION REVEAL INTRA-TUMOUR HETEROGENEITY AND IDENTIFY DISULfiRAM AND COPPER AS A SYNERGISTIC THERAPY IN PAEDIATRIC EPENDYMOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii10, https://doi.org/10.1093/neuonc/noae158.037
VASARI-AUTO: PERFORMANT, EQUITABLE, EffiCIENT, ECONOMIC, AND SURVIVAL PREDICTIVE FEATURISATION OF GLIOMA MRI
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii10, https://doi.org/10.1093/neuonc/noae158.038
INTEGRATING TRANSCRIPTOMICS WITH SPATIAL RADIOGRAPHIC ATLASES FOR GLIOMA ANALYSIS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii10, https://doi.org/10.1093/neuonc/noae158.039
PROLONGED SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA: CASE REPORTS, LITERATURE REVIEW AND CURRENT PERSPECTIVES OF MOLECULAR BEHAVIOR
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii10–vii11, https://doi.org/10.1093/neuonc/noae158.040
SURGICAL OUTCOMES OF TUBULAR RETRACTOR SYSTEMS IN THE MANAGEMENT OF BRAIN TUMOURS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii11, https://doi.org/10.1093/neuonc/noae158.041
DESIGN AND SET UP OF A RANDOMISED CONTROLLED TRIAL OF MEDICINAL CANNABINOIDS IN RECURRENT GLIOBLASTOMA - THE ARISTOCRAT TRIAL
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii11, https://doi.org/10.1093/neuonc/noae158.042
ABNORMAL CORTICAL EXCITABILITY IS ASSOCIATED WITH DECREASED OVERALL SURVIVAL IN PATIENTS WITH GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii11, https://doi.org/10.1093/neuonc/noae158.043
ORTHOPTIST LED VISUAL fiELD MONITORING DURING AWAKE CRANIOTOMY OF LOW GRADE GLIOMA: A UK TERTIARY CENTRE EXPERIENCE
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii11–vii12, https://doi.org/10.1093/neuonc/noae158.044
IMPACT OF DNA METHYLATION PROfiLING IN REfiNING MENINGIOMA RECURRENCE RISK STRATIfiCATION AND CLINICAL FOLLOW UP
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii12, https://doi.org/10.1093/neuonc/noae158.045
PROTAC’ING CENTROSOME AMPLIfiCATION PROTEINS: TARGETED PROTEIN DEGRADATION AS A NOVEL THERAPEUTIC STRATEGY IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii12, https://doi.org/10.1093/neuonc/noae158.046
DEVELOPMENT OF A HUMAN-SPECIfiC 3D IN VITRO PAEDIATRIC CEREBELLAR TUMOUR MODEL USING DECELLULARISED BRAIN AUTOPSY TISSUE
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii12, https://doi.org/10.1093/neuonc/noae158.047
MATHEMATICAL MODELLING OF SURVIVAL IN LOW GRADE GLIOMAS AT MALIGNANT TRANSFORMATION WITH XGBOOST
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii12–vii13, https://doi.org/10.1093/neuonc/noae158.048
THE EffiCACY OF GAMMA KNIFE RADIOSURGERY FOR CYSTIC METASTASIS COMPARED WITH NON-CYSTIC METASTASIS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii13, https://doi.org/10.1093/neuonc/noae158.049
THE IMPACT OF THE FRONTAL ASLANT TRACT ON POST-OPERATIVE OUTCOMES IN GLIOMA SURGERY
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii13, https://doi.org/10.1093/neuonc/noae158.050
WHOLE BRAIN RADIOTHERAPY FOR INTRACRANIAL METASTATIC DISEASE IN NON-SMALL CELL LUNG CANCER: THE WESSEX EXPERIENCE
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii13, https://doi.org/10.1093/neuonc/noae158.051
AN ANALYSIS OF THE PATIENT REPORT OUTCOMES OF A JOINT CNS / AHP NEURO-ONCOLOGY CLINIC ON PATIENTS QUALITY OF LIFE
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii13–vii14, https://doi.org/10.1093/neuonc/noae158.052
ANALYSING THE RATE OF RECURRENCE AND LEPTOMENINGEAL DISEASE IN POSTERIOR FOSSA BRAIN METASTASES FOLLOWING POSTOPERATIVE RADIOTHERAPY- SINGLE CENTRE EXPERIENCE
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii14, https://doi.org/10.1093/neuonc/noae158.053
RISKS AND OUTCOMES OF STROKE IN PATIENTS WITH PRIMARY BRAIN AND MENINGEAL TUMOURS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii14, https://doi.org/10.1093/neuonc/noae158.054
ARGININE DEPRIVATION SENSITISES GBM CELLS TO RADIATION THROUGH DOWNREGULATION OF DNA REPAIR PATHWAYS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii14, https://doi.org/10.1093/neuonc/noae158.055
DEXAMETHASONE WEAN POST CRANIOTOMY FOR MENINGIOMA- A CASE STUDY
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii14, https://doi.org/10.1093/neuonc/noae158.056
DYSREGULATION OF M6A RNA METHYLATION, R-LOOPS AND THE DNA DAMAGE RESPONSE IN PAEDIATRIC HIGH-GRADE GLIOMAS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii14–vii15, https://doi.org/10.1093/neuonc/noae158.057
LONG-TERM SURVIVAL OF TANYCYTIC EPENDYMOMA OF LATERAL VENTRICLE WITH ADJACENT FRONTAL LOBE INVASION: CASE REPORT AND LITERATURE REVIEW
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii15, https://doi.org/10.1093/neuonc/noae158.058
VALIDATION OF 2HG-TARGETTED MR SPECTROSCOPY FOR IDENTIFYING IDH-MUTANT GLIOMAS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii15, https://doi.org/10.1093/neuonc/noae158.059
IDENTIFYING YB1 AND NPM1 AS PART OF THE MUTANT HISTONE 3 PROTEIN INTERACTOME IN H3 MUTATED PHGG
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii15, https://doi.org/10.1093/neuonc/noae158.060
MENINGIOMA SIZE IS POSITIVELY CORRELATED WITH TUMOR WHO GRADE
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii15–vii16, https://doi.org/10.1093/neuonc/noae158.061
INVESTIGATING CUDC-101 EFFECT AND MECHANISM OF ACTION AGAINST GLIOBLASTOMA IN VITRO
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii16, https://doi.org/10.1093/neuonc/noae158.062
METABOLOMIC PROfiLING OF ASTROCYTE-GLIOBLASTOMA CELL INTERACTION IN A POSTOPERATIVE TUMOUR MICROENVIRONMENT MODEL
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii16, https://doi.org/10.1093/neuonc/noae158.063
SUPERSOFT SPONGE-LIKE CRYOGEL AS AN IMPLANT TO TREAT GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii16, https://doi.org/10.1093/neuonc/noae158.064
NANOPORE-BASED INTRA-OPERATIVE CLASSIfiCATION OF CENTRAL NERVOUS SYSTEM TUMOURS IN THE NHS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii16–vii17, https://doi.org/10.1093/neuonc/noae158.065
IMPROVING THE EffiCIENCY OF THE NEURO-ONCOLOGY NEW PATIENT CLINIC AT THE ROYAL MARSDEN HOSPITAL
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii17, https://doi.org/10.1093/neuonc/noae158.066
STUDIES ON GLYCOGEN PHOSPHORYLASE AS A POTENTIAL MOLECULAR TARGET IN GLIOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii17, https://doi.org/10.1093/neuonc/noae158.067
WHICH BRAIN TUMOUR PATIENTS WOULD BENEfiT FROM SURGERY TO TREAT BOTH THE TUMOUR AND TUMOUR-RELATED EPILEPSY?
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii17, https://doi.org/10.1093/neuonc/noae158.068
EXPLORING MOLECULAR LINKS IN BRAIN TUMOUR BIOPSY TISSUES AND ALZHEIMER’S DISEASE
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii17, https://doi.org/10.1093/neuonc/noae158.069
OCCUPATIONAL THERAPY PRE-ASSESSMENT OF LOW GRADE GLIOMA PATIENT WITH COMPLEX NEEDS ALMOST HALVES POST-OPERATIVE LENGTH OF STAY
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii17–vii18, https://doi.org/10.1093/neuonc/noae158.070
M6A RNA METHYLATION AS A THERAPEUTIC TARGET IN HIGH GRADE GLIOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii18, https://doi.org/10.1093/neuonc/noae158.071
DO NEURO ONCOLOGY PATIENTS FEEL SUffiCIENTLY SUPPORTED TO MANAGE THEIR SURGICAL WOUNDS AFTER SURGERY?
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii18, https://doi.org/10.1093/neuonc/noae158.072
GENES ENCODING CELL SURFACE RECEPTORS AS NOVEL PROGNOSIS BIOMARKERS IN BRAIN TUMORS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii18, https://doi.org/10.1093/neuonc/noae158.073
PCV ALONE IN GRADE 2 AND GRADE 3 OLIGODENDROGLIOMA – LONG-TERM RESULTS FROM A UK TERTIARY CARE CENTRE
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii18–vii19, https://doi.org/10.1093/neuonc/noae158.074
SINGLE INSTITUTION RETROSPECTIVE ANALYSIS OF COMPLICATIONS ASSOCIATED WITH SURGICAL DEBULKING OF BRAIN METASTASIS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii19, https://doi.org/10.1093/neuonc/noae158.075
MENINGIOMA OEDEMA AND SEIZURES – A META-ANALYSIS
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii19, https://doi.org/10.1093/neuonc/noae158.076
EPIGENETIC MODULATION OF STEMNESS AND DIFFERENTIATION BY VALPROIC ACID IN MEDULLOBLASTOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii19, https://doi.org/10.1093/neuonc/noae158.077
INTRAOPERATIVE MRI FOR BRAIN TUMOURS: A 15-YEAR RETROSPECTIVE REVIEW AT A SINGLE AUSTRALIAN INSTITUTION
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii19, https://doi.org/10.1093/neuonc/noae158.078
RE-VISITING BIOPSIES FOR SUSPECTED CNS LYMPHOMAS: TO BIOPSY OR NOT TO BIOPSY?
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii19–vii20, https://doi.org/10.1093/neuonc/noae158.079
A NEW INTERNATIONAL ACCELERATOR PROGRAMME FOR NOVEL BRAIN TUMOUR THERAPIES
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii20, https://doi.org/10.1093/neuonc/noae158.080
EVALUATING GLIOMA PATIENT PERCEPTIONS TOWARDS REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION FOR REHABILITATION
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii20, https://doi.org/10.1093/neuonc/noae158.081
HAS THE INITIATION OF A FORMAL PATHWAY FOR TUMOUR TISSUE COLLECTION IN NEURO ONCOLOGY PATIENTS LED TO AN INCREASE IN PATIENT’S HAVING WHOLE GENOME SEQUENCING (WGS), AND HOW WILL THIS IMPACT ONCOLOGY MANAGEMENT IN THE FUTURE?
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii20, https://doi.org/10.1093/neuonc/noae158.082
THE UTILITY OF MULTIPARAMETRIC MRI IN REDUCING DIAGNOSTIC UNCERTAINTY FOR PRIMARY CNS LYMPHOMA
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii20–vii21, https://doi.org/10.1093/neuonc/noae158.083
USING CCA-MRI TO PREDICT RESPONSE TO STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii21, https://doi.org/10.1093/neuonc/noae158.084
MGMT METHYLATION AND ITS PROGNOSTIC SIGNIfiCANCE IN INOPERABLE IDH WILDTYPE GLIOBLASTOMA: A SIX-YEAR REVIEW AT A TERTIARY NEURO-ONCOLOGY CENTER
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii21, https://doi.org/10.1093/neuonc/noae158.085
UNDERSTANDING THE MANAGEMENT OF MALIGNANT GLIOMAS DURING COVID-19 PANDEMIC IN A HIGH VOLUME TERTIARY GOVERNMENT HOSPITAL IN THE PHILIPPINES
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii21, https://doi.org/10.1093/neuonc/noae158.086
MULTI-AGENCY DEVELOPMENT OF A NEW INFORMATION RESOURCE FOR PATIENTS WITH BRAIN METASTASES
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Pages vii21–vii22, https://doi.org/10.1093/neuonc/noae158.087
AUDIT TO EVALUATE CURRENT RADIOTHERAPY (RT) PLANNING PATHWAY: COULD CURRENT PRACTICE BE IMPROVED BY THE TIMING OF MAGNETIC RESONANCE IMAGING (MRI)?
Neuro-Oncology, Volume 26, Issue Supplement_7, October 2024, Page vii22, https://doi.org/10.1093/neuonc/noae158.088
